❌

Normal view

ConSensus: Multi-Agent Collaboration for Multimodal Sensing

arXiv:2601.06453v1 Announce Type: new Abstract: Large language models (LLMs) are increasingly grounded in sensor data to perceive and reason about human physiology and the physical world. However, accurately interpreting heterogeneous multimodal sensor data remains a fundamental challenge. We show that a single monolithic LLM often fails to reason coherently across modalities, leading to incomplete interpretations and prior-knowledge bias. We introduce ConSensus, a training-free multi-agent collaboration framework that decomposes multimodal sensing tasks into specialized, modality-aware agents. To aggregate agent-level interpretations, we propose a hybrid fusion mechanism that balances semantic aggregation, which enables cross-modal reasoning and contextual understanding, with statistical consensus, which provides robustness through agreement across modalities. While each approach has complementary failure modes, their combination enables reliable inference under sensor noise and missing data. We evaluate ConSensus on five diverse multimodal sensing benchmarks, demonstrating an average accuracy improvement of 7.1% over the single-agent baseline. Furthermore, ConSensus matches or exceeds the performance of iterative multi-agent debate methods while achieving a 12.7 times reduction in average fusion token cost through a single-round hybrid fusion protocol, yielding a robust and efficient solution for real-world multimodal sensing tasks.

A Large-Scale Study on the Development and Issues of Multi-Agent AI Systems

arXiv:2601.07136v1 Announce Type: cross Abstract: The rapid emergence of multi-agent AI systems (MAS), including LangChain, CrewAI, and AutoGen, has shaped how large language model (LLM) applications are developed and orchestrated. However, little is known about how these systems evolve and are maintained in practice. This paper presents the first large-scale empirical study of open-source MAS, analyzing over 42K unique commits and over 4.7K resolved issues across eight leading systems. Our analysis identifies three distinct development profiles: sustained, steady, and burst-driven. These profiles reflect substantial variation in ecosystem maturity. Perfective commits constitute 40.8% of all changes, suggesting that feature enhancement is prioritized over corrective maintenance (27.4%) and adaptive updates (24.3%). Data about issues shows that the most frequent concerns involve bugs (22%), infrastructure (14%), and agent coordination challenges (10%). Issue reporting also increased sharply across all frameworks starting in 2023. Median resolution times range from under one day to about two weeks, with distributions skewed toward fast responses but a minority of issues requiring extended attention. These results highlight both the momentum and the fragility of the current ecosystem, emphasizing the need for improved testing infrastructure, documentation quality, and maintenance practices to ensure long-term reliability and sustainability.

app.build: A Production Framework for Scaling Agentic Prompt-to-App Generation with Environment Scaffolding

arXiv:2509.03310v2 Announce Type: replace Abstract: We present app.build (https://github.com/neondatabase/appdotbuild-agent), an open-source framework that improves LLM-based application generation through systematic validation and structured environments. Our approach combines multi-layered validation pipelines, stack-specific orchestration, and model-agnostic architecture, implemented across three reference stacks. Through evaluation on 30 generation tasks, we demonstrate that comprehensive validation achieves 73.3% viability rate with 30% reaching perfect quality scores, while open-weights models achieve 80.8% of closed-model performance when provided structured environments. The open-source framework has been adopted by the community, with over 3,000 applications generated to date. This work demonstrates that scaling reliable AI agents requires scaling environments, not just models -- providing empirical insights and complete reference implementations for production-oriented agent systems.

Key Information Influencing Patient Decision-Making About AI in Health Care: Survey Experiment Study

Background: Artificial Intelligence (AI)-enabled devices are increasingly used in healthcare. However, there has been limited research on patients’ informational preferences, including which elements of AI device labeling enhance patient understanding, trust, and acceptance. Clear and effective patient-facing communication is essential to address patient concerns and support informed decision-making regarding AI-enabled care. Objective: Using simulated AI device labels in a cardiovascular context, we evaluated three aims. First, we identified key information elements that influence patient trust and acceptance of an AI device. Second, we examined how these effects varied based on patient characteristics. Third, we explored how patients evaluated informational content of AI labels and their perceived effectiveness of the AI labels in informing decision-making about the use of AI device, building trust in the device, and shaping their intention to use it in their healthcare. Methods: We recruited 340 US patients from ResearchMatch.org to participate in a web-based survey that contained two experiments. In the discrete choice experiment (DCE), participants indicated preferences in terms of trust and acceptance regarding 16 pairs of simulated AI device labels that varied across eight types of information needs identified in our previous qualitative work. In the single profile factorial experiment (SPFE), participants evaluated four randomly assigned label prototypes regarding the label’s legibility, comprehensibility, information overload, credibility, and perceived effectiveness in informing about the AI device, as well as participants’ trust in the AI device and intention to use the device in their healthcare. Data was analyzed using mixed effects binary or ordinal logistic regression. Results: The DCE showed that information about regulatory approval, high device performance, provider oversight, and AI’s value added to usual care significantly increased the likelihood of patient trust by 14.1-19.3% and acceptance by 13.3-17.9%. Subgroup analyses revealed variations based on patient characteristics such as familiarity with AI, health literacy, and recency of last medical checkup. The SPFE showed that patients reported good label comprehension, and that information about provider oversight, regulatory approval, device performance, and AI’s added value improved perceived credibility and effectiveness of the AI label (odds ratios [ORs] range 1.35-2.05), reduced doubts in the AI device (ORs range 0.61- 0.77), and increased trust and intention to use the AI device (ORs range 1.47-1.73). However, information about data privacy and safety management protocols are less influential. Conclusions: Patients value information about an AI device’s performance, provider oversight, regulatory status, and added value during decision-making. Providing transparent, easily understandable information about these aspects is critical to support patient determinations of trust and acceptance of AI-enabled healthcare. Information elements’ impact on patient trust and acceptance varies by patient characteristics, highlighting the need for a tailored approach to address the concerns of diverse patient groups about AI in healthcare.

FACTS Benchmark Suite Introduced to Evaluate Factual Accuracy of Large Language Models

12 January 2026 at 15:55

A new industry benchmark aimed at systematically evaluating the factual accuracy of LLMs has been released with the launch of the FACTS Benchmark Suite. Developed by the FACTS team in collaboration with Kaggle, the suite expands earlier work on factual grounding and introduces a broader, multi-dimensional framework for measuring how reliably language models produce factually correct responses.

By Robert Krzaczyński

The Evaluation Gap in Medicine, AI and LLMs: Navigating Elusive Ground Truth & Uncertainty via a Probabilistic Paradigm

arXiv:2601.05500v1 Announce Type: new Abstract: Benchmarking the relative capabilities of AI systems, including Large Language Models (LLMs) and Vision Models, typically ignores the impact of uncertainty in the underlying ground truth answers from experts. This ambiguity is particularly consequential in medicine where uncertainty is pervasive. In this paper, we introduce a probabilistic paradigm to theoretically explain how high certainty in ground truth answers is almost always necessary for even an expert to achieve high scores, whereas in datasets with high variation in ground truth answers there may be little difference between a random labeller and an expert. Therefore, ignoring uncertainty in ground truth evaluation data can result in the misleading conclusion that a non-expert has similar performance to that of an expert. Using the probabilistic paradigm, we thus bring forth the concepts of expected accuracy and expected F1 to estimate the score an expert human or system can achieve given ground truth answer variability. Our work leads to the recommendation that when establishing the capability of a system, results should be stratified by probability of the ground truth answer, typically measured by the agreement rate of ground truth experts. Stratification becomes critical when the overall performance drops below a threshold of 80%. Under stratified evaluation, performance comparison becomes more reliable in high certainty bins, mitigating the effect of the key confounding factor -- uncertainty.

Benchmarking LLM-based Agents for Single-cell Omics Analysis

arXiv:2508.13201v2 Announce Type: replace-cross Abstract: The surge in multimodal single-cell omics data exposes limitations in traditional, manually defined analysis workflows. AI agents offer a paradigm shift, enabling adaptive planning, executable code generation, traceable decisions, and real-time knowledge fusion. However, the lack of a comprehensive benchmark critically hinders progress. We introduce a novel benchmarking evaluation system to rigorously assess agent capabilities in single-cell omics analysis. This system comprises: a unified platform compatible with diverse agent frameworks and LLMs; multidimensional metrics assessing cognitive program synthesis, collaboration, execution efficiency, bioinformatics knowledge integration, and task completion quality; and 50 diverse real-world single-cell omics analysis tasks spanning multi-omics, species, and sequencing technologies. Our evaluation reveals that Grok-3-beta achieves state-of-the-art performance among tested agent frameworks. Multi-agent frameworks significantly enhance collaboration and execution efficiency over single-agent approaches through specialized role division. Attribution analyses of agent capabilities identify that high-quality code generation is crucial for task success, and self-reflection has the most significant overall impact, followed by retrieval-augmented generation (RAG) and planning. This work highlights persistent challenges in code generation, long-context handling, and context-aware knowledge retrieval, providing a critical empirical foundation and best practices for developing robust AI agents in computational biology.

Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making

Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.

PMID:41514607 | PMC:PMC12784771 | DOI:10.3390/cancers18010094

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z

Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-y

In a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.

Sci-Reasoning: A Dataset Decoding AI Innovation Patterns

arXiv:2601.04577v1 Announce Type: new Abstract: While AI innovation accelerates rapidly, the intellectual process behind breakthroughs -- how researchers identify gaps, synthesize prior work, and generate insights -- remains poorly understood. The lack of structured data on scientific reasoning hinders systematic analysis and development of AI research agents. We introduce Sci-Reasoning, the first dataset capturing the intellectual synthesis behind high-quality AI research. Using community-validated quality signals and an LLM-accelerated, human-verified pipeline, we trace Oral and Spotlight papers across NeurIPS, ICML, and ICLR (2023-2025) to its key predecessors, articulating specific reasoning links in a structured format. Our analysis identifies 15 distinct thinking patterns, with three dominant strategies accounting for 52.7%: Gap-Driven Reframing (24.2%), Cross-Domain Synthesis (18.0%), and Representation Shift (10.5%). The most powerful innovation recipes combine multiple patterns: Gap-Driven Reframing + Representation Shift, Cross-Domain Synthesis + Representation Shift, and Gap-Driven Reframing + Cross-Domain Synthesis. This dataset enables quantitative studies of scientific progress and provides structured reasoning trajectories for training the next generation AI research agents.

Self-MedRAG: a Self-Reflective Hybrid Retrieval-Augmented Generation Framework for Reliable Medical Question Answering

arXiv:2601.04531v1 Announce Type: cross Abstract: Large Language Models (LLMs) have demonstrated significant potential in medical Question Answering (QA), yet they remain prone to hallucinations and ungrounded reasoning, limiting their reliability in high-stakes clinical scenarios. While Retrieval-Augmented Generation (RAG) mitigates these issues by incorporating external knowledge, conventional single-shot retrieval often fails to resolve complex biomedical queries requiring multi-step inference. To address this, we propose Self-MedRAG, a self-reflective hybrid framework designed to mimic the iterative hypothesis-verification process of clinical reasoning. Self-MedRAG integrates a hybrid retrieval strategy, combining sparse (BM25) and dense (Contriever) retrievers via Reciprocal Rank Fusion (RRF) to maximize evidence coverage. It employs a generator to produce answers with supporting rationales, which are then assessed by a lightweight self-reflection module using Natural Language Inference (NLI) or LLM-based verification. If the rationale lacks sufficient evidentiary support, the system autonomously reformulates the query and iterates to refine the context. We evaluated Self-MedRAG on the MedQA and PubMedQA benchmarks. The results demonstrate that our hybrid retrieval approach significantly outperforms single-retriever baselines. Furthermore, the inclusion of the self-reflective loop yielded substantial gains, increasing accuracy on MedQA from 80.00% to 83.33% and on PubMedQA from 69.10% to 79.82%. These findings confirm that integrating hybrid retrieval with iterative, evidence-based self-reflection effectively reduces unsupported claims and enhances the clinical reliability of LLM-based systems.

Atlas 2 -- Foundation models for clinical deployment

arXiv:2601.05148v1 Announce Type: cross Abstract: Pathology foundation models substantially advanced the possibilities in computational pathology -- yet tradeoffs in terms of performance, robustness, and computational requirements remained, which limited their clinical deployment. In this report, we present Atlas 2, Atlas 2-B, and Atlas 2-S, three pathology vision foundation models which bridge these shortcomings by showing state-of-the-art performance in prediction performance, robustness, and resource efficiency in a comprehensive evaluation across eighty public benchmarks. Our models were trained on the largest pathology foundation model dataset to date comprising 5.5 million histopathology whole slide images, collected from three medical institutions Charit\'e - Universt\"atsmedizin Berlin, LMU Munich, and Mayo Clinic.

Multi-Modal AI for Remote Patient Monitoring in Cancer Care

arXiv:2512.00949v2 Announce Type: replace-cross Abstract: For patients undergoing systemic cancer therapy, the time between clinic visits is full of uncertainties and risks of unmonitored side effects. To bridge this gap in care, we developed and prospectively trialed a multi-modal AI framework for remote patient monitoring (RPM). This system integrates multi-modal data from the HALO-X platform, such as demographics, wearable sensors, daily surveys, and clinical events. Our observational trial is one of the largest of its kind and has collected over 2.1 million data points (6,080 patient-days) of monitoring from 84 patients. We developed and adapted a multi-modal AI model to handle the asynchronous and incomplete nature of real-world RPM data, forecasting a continuous risk of future adverse events. The model achieved an accuracy of 83.9% (AUROC=0.70). Notably, the model identified previous treatments, wellness check-ins, and daily maximum heart rate as key predictive features. A case study demonstrated the model's ability to provide early warnings by outputting escalating risk profiles prior to the event. This work establishes the feasibility of multi-modal AI RPM for cancer care and offers a path toward more proactive patient support.(Accepted at Europe NeurIPS 2025 Multimodal Representation Learning for Healthcare Workshop. Best Paper Poster Award.)

Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study

Background: Structured medication reviews (SMRs) are an essential component of medication optimization, especially for patients with multimorbidity and polypharmacy. However, the process remains challenging due to the complexities of patient data, time constraints, and the need for coordination among health care professionals (HCPs). This study explores HCPs’ perspectives on the integration of artificial intelligence (AI)–assisted tools to enhance the SMR process, with a focus on the potential benefits of and barriers to adoption. Objective: This study aims to identify the key user requirements for AI-assisted tools to improve the efficiency and effectiveness of SMRs, specifically for patients with multimorbidity, complex polypharmacy, and frailty. Methods: A qualitative study was conducted involving focus groups and semistructured interviews with HCPs and patients in the United Kingdom. Participants included physicians, pharmacists, clinical pharmacologists, psychiatrists from primary and secondary care, a policy maker, and patients with multimorbidity. Data were analyzed using a hybrid inductive and deductive thematic analysis approach to identify themes related to AI-assisted tool functionality, workflow integration, user-interface visualization, and usability in the SMR process. Results: Four major themes emerged from the analysis: innovative AI potential, optimizing electronic patient record visualization, functionality of the AI tool for SMRs, and facilitators of and barriers to AI tool implementation. HCPs identified the potential of AI to support patient identification and prioritizing those at risk of medication-related harm. AI-assisted tools were viewed as essential in detecting prescribing gaps, drug interactions, and patient risk trajectories over time. Participants emphasized the importance of presenting patient data in an intuitive format, with a patient interface for shared decision-making. Suggestions included color-coding blood results, highlighting critical medication reviews, and providing timelines of patient medical histories. HCPs stressed the need for AI tools to integrate seamlessly with existing electronic patient record systems and provide actionable insights without overwhelming users with excessive notifications or “pop-up” alerts. Factors influencing the uptake of AI-assisted tools included the need for user-friendly design, evidence of tool effectiveness (though some were skeptical about the predictive accuracy of AI models), and addressing concerns around digital exclusion. Conclusions: The findings highlight the potential for AI-assisted tools to streamline and optimize the SMR process, particularly for patients with multimorbidity and complex polypharmacy. However, successful implementation depends on addressing concerns related to workflow integration, user acceptance, and evidence of effectiveness. User-centered design is crucial to ensure that AI-assisted tools support HCPs in delivering high-quality, patient-centered care while minimizing cognitive overload and alert fatigue.

Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19

Background: The rapid growth of social media as an information channel has enabled the swift spread of inaccurate or false health information, significantly impacting public health. This widespread dissemination of misinformation has caused confusion, eroded trust in health authorities, led to noncompliance with health guidelines, and encouraged risky health behaviors. Understanding the dynamics of misinformation on social media is essential for devising effective public health communication strategies. Objective: This study aims to present a comprehensive and automated approach that leverages Large Language Models (LLMs) and Machine Learning (ML) techniques to detect misinformation on social media, uncover the underlying causes and themes, and generate refutation arguments, facilitating control of its spread and promoting public health outcomes by inoculating people against health misinformation. Methods: We use two datasets to train three LLMs, namely BERT, T5, and GPT-2, to classify documents into two categories: misinformation and non-misinformation. Additionally, we employ a separate dataset to identify misinformation topics. To analyze these topics, we applied three topic modeling algorithms—Latent Dirichlet Allocation (LDA), Top2Vec, and BERTopic—and selected the optimal model based on performance evaluated across three metrics. Using a prompting approach, we extract sentence-level representations for the topics to uncover their underlying themes. Finally, we design a prompt text capable of identifying misinformation themes effectively. Codes are available at https://github.com/SamiraMalek/MDIP-MDIS. Results: The trained BERT model demonstrated exceptional performance, achieving 98% accuracy in classifying misinformation and non-misinformation, with a 44% reduction in false positive rates for AI-generated misinformation. Among the three topic modeling approaches employed, BERTopic outperformed the others, achieving the highest metrics with a Coherence Value (CV) of 0.41, Normalized Pointwise Mutual Information (NPMI) of -0.086, and Inverted RBO (IRBO) of 0.99. To address the issue of unclassified documents, we developed an algorithm to assign each document to its closest topic. Additionally, we proposed a novel method using prompt engineering to generate sentence-level representations for each topic, achieving a 99.6% approval rate as "appropriate" or "somewhat appropriate" by three independent raters. We further designed a prompt text to identify themes of misinformation topics and developed another prompt capable of detecting misinformation themes with 82% accuracy. Conclusions: This study presents a comprehensive and automated approach to addressing health misinformation on social media using advanced machine learning and natural language processing techniques. By leveraging large language models (LLMs) and prompt engineering, the system effectively detects misinformation, identifies underlying themes, and provides explanatory responses to combat its spread. The proposed method was tested on an English-language COVID-19–related dataset and has not been evaluated on real-world online social media data; the experiments were conducted offline.

Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine

J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.

ABSTRACT

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tumor and offer a promising platform for drug screening, biomarker development, and personalized therapy. However, a systematic evaluation of their translational capacities is lacking.

METHODS: A systematic review was conducted according to the PRISMA 2020 guidelines (PROSPERO registration pending) using PubMed, EMBASE, and Cochrane CENTRAL (December 10, 2024) to identify English-language PDAC PDO studies that incorporated therapeutic testing. Ninety-five studies met the inclusion criteria. Data extraction captured >75 variables per study, including spanning culture methodology, therapeutic profiling, biomarker integration, and clinical correlation. A 13-domain weighted Translatability Scoring Framework adapted from Wehling et al. assessed predictive validity, biomarker strength, pharmacogenetics, and clinical trial alignment. Scores ranged from 0 to 5 and were categorized as good (>4.0), moderate (3.0-4.0), or low (<3.0) translational potential.

RESULTS: Of the 95 studies, 70.5% have been published since 2021, reflecting the rapid growth in this field. The mean PDO generation success rate was 89.7%, with the primary tumor tissue being the predominant source (48.4%). Only 24.8% were directly linked to clinical trials and 5.3% incorporated multi-omic profiling. The median translatability score was 3.13 (range, 1.72-4.59): 45.3% of the studies had low translatability, 50.5% moderate, and only 4.2% had good translational potential. High-scoring studies consistently combine multi-omic biomarker platforms, in vivo validation, clinical outcome correlation, and prospective trial integration. Conversely, the weakest domains were pharmacogenetics, endpoint strategies, and biomarker validation, limiting their overall clinical relevance.

CONCLUSIONS: PDOs have demonstrated strong feasibility and in vitro clinical correlation in PDAC; however, their clinical translation remains constrained by limited multi-omic integration, absence of pharmacogenomic modeling, and sparse clinical trial embedding. Standardization of protocols, adoption of harmonized and clinically relevant endpoints, and systematic incorporation of biomarker-driven co-clinical trial frameworks are urgently needed to transition PDOs from promising experimental surrogates to validating precision oncology tools capable of informing therapeutic decision-making in PDAC.

PMID:41495743 | DOI:10.1186/s12967-025-07596-8

❌